Inhibitor

Bibliography

Biblio print

Tree Display

AceDB Schema

XML Display

Feedback

Inhibitor Report for: t-MTUCB

Canine sEH IC50 2.0 +/- 0.3 ng/mL (compared to 0.4 for t-TUCB


General
Type Urea derivative, Multitarget
Chemical_Nomenclature trans-4-{4-[3-methyl-3-(4-trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid
Canonical SMILES C1=CC(=CC=C1OC(F)(F)F)N(C(N(C2CCC(CC2)OC3=CC=C(C=C3)C(O[H])=O)[H])=O)C.C([H])([H])([H])[H].C
InChI InChI=1S/C22H23F3N2O5/c1-27(16-6-12-19(13-7-16)32-22(23,24)25)21(30)26-15-4-10-18(11-5-15)31-17-8-2-14(3-9-17)20(28)29/h2-3,6-9,12-13,15,18H,4-5,10-11H2,1H3,(H,26,30)(H,28,29)
InChIKey JSTOWLAYLPNZNS-UHFFFAOYSA-N
Other name(s) EC3039
________________________________________________________________________________________________
MW|452.43
Formula|C22H23F3N2O5
CAS_number|
PubChem|
UniChem|JSTOWLAYLPNZNS-UHFFFAOYSA-N
IUPHAR|
Wikipedia|

Target
Families | t-MTUCB ligand of proteins in family: Epoxide_hydrolase
Protein | human-EPHX2, mouse-hyes

References:
Search PubMed for references concerning: t-MTUCB
    Title: Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis
    McReynolds CB, Hwang SH, Yang J, Wan D, Wagner K, Morisseau C, Li D, Schmidt WK, Hammock BD
    Ref: Front Pharmacol, 10:533, 2019 : PubMed

            

    Title: Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB
    Wecksler AT, Hwang SH, Wettersten HI, Gilda JE, Patton A, Leon LJ, Carraway KL, 3rd, Gomes AV, Baar K and Hammock BD <1 more author(s)>
    Ref: Anticancer Drugs, 25:433, 2014 : PubMed